<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recommendations for initial treatment of chronic hepatitis B in nonpregnant adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recommendations for initial treatment of chronic hepatitis B in nonpregnant adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Recommendations for initial treatment of chronic hepatitis B in nonpregnant adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="12%"></colgroup><colgroup width="64%"></colgroup> <tbody> <tr> <td class="subtitle1">HBeAg</td> <td class="subtitle1">HBV DNA<br/> (PCR)</td> <td class="subtitle1">ALT</td> <td class="subtitle1">Treatment strategy</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Patients without cirrhosis*</td> </tr> <tr class="highlight_gray_text"> <td class="centered" rowspan="2">+</td> <td rowspan="2">&gt;20,000 international units/mL</td> <td rowspan="2">≤2 x ULN<sup>¶</sup></td> <td>Treatment is not recommended, because current treatment has low efficacy in inducing HBeAg seroconversion. Treatment may be considered in older patients (&gt;40 years) and in those with family history of HCC.</td> </tr> <tr class="highlight_gray_text"> <td>Patients should be monitored<sup>Δ</sup> and treatment considered if ALT becomes elevated &gt;2 x ULN, liver biopsy shows moderate/severe inflammation or fibrosis<sup>◊</sup> (eg, METAVIR score ≥F2), and/or noninvasive testing suggests moderate/severe fibrosis.</td> </tr> <tr> <td class="centered" rowspan="7">+</td> <td rowspan="7">&gt;20,000 international units/mL</td> <td rowspan="7">&gt;2 x ULN<sup>¶</sup></td> <td>Observe for 3 to 6 months if compensated and treat if no spontaneous HBeAg loss.</td> </tr> <tr> <td>Immediate treatment if severe hepatitis flare (eg, icteric or clinical decompensation).</td> </tr> <tr> <td>ETV, TAF, TDF, or PegIFN alfa are preferred for initial therapy.<sup>§</sup><sup>¥</sup></td> </tr> <tr> <td>End-point of treatment <span style="font-size: 10pt; font-family: 'Verdana',sans-serif;">–</span> Seroconversion from HBeAg to anti-HBe.<sup>‡</sup></td> </tr> <tr> <td class="sublist1_start">Duration of therapy:</td> </tr> <tr> <td class="indent1"> <ul> <li>PegIFN alfa: 48 weeks. </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>ETV, TAF, or TDF: Continue for at least 12 months after HBeAg seroconversion. </li> </ul> </td> </tr> <tr class="highlight_gray_text"> <td class="centered" rowspan="5">–</td> <td rowspan="5">&gt;2000 international units/mL</td> <td rowspan="5"> <p>&gt;2 x ULN<sup>¶</sup></p> <p>OR</p> 1 to 2 x ULN<sup>¶</sup> if liver biopsy shows moderate/severe necroinflammation or significant fibrosis<sup>◊</sup> (eg, METAVIR score ≥F2) or non-invasive testing shows significant fibrosis</td> <td>ETV, TAF, TDF, or PegIFN alfa are preferred for initial therapy.<sup>§</sup><sup>¥</sup></td> </tr> <tr class="highlight_gray_text"> <td>End-point of treatment <span style="font-size: 10pt; font-family: 'Verdana',sans-serif;">–</span> HBsAg loss.</td> </tr> <tr class="highlight_gray_text"> <td class="sublist1_start">Duration of therapy:</td> </tr> <tr class="highlight_gray_text"> <td class="indent1"> <ul> <li>PegIFN alfa: One year. </li> </ul> </td> </tr> <tr class="highlight_gray_text"> <td class="indent1"> <ul> <li>ETV, TAF, or TDF: Several years or indefinite.<sup>†</sup> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">–</td> <td>≤2000 international units/mL</td> <td>≤ULN<sup>¶</sup></td> <td>Monitor and treat if HBV DNA and ALT increase as described above.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Patients with cirrhosis*</td> </tr> <tr class="highlight_gray_text"> <td class="centered" rowspan="5">+/–</td> <td rowspan="5">Detectable</td> <td rowspan="5">Any ALT</td> <td class="sublist1_start">Compensated:</td> </tr> <tr class="highlight_gray_text"> <td class="indent1"> <ul> <li>HBV DNA &gt;2000 international units/mL <span style="font-size: 10pt; font-family: 'Verdana',sans-serif;">–</span> Treat with ETV, TAF, or TDF.<sup>§</sup><sup>¥</sup> Treatment should be continued indefinitely.** </li> </ul> </td> </tr> <tr class="highlight_gray_text"> <td class="indent1"> <ul> <li>HBV DNA &lt;2000 international units/mL <span style="font-size: 10pt; font-family: 'Verdana',sans-serif;">–</span> Consider treatment particularly if ALT elevated; close monitoring if treatment is not initiated. </li> </ul> </td> </tr> <tr class="highlight_gray_text"> <td class="sublist1_start">Decompensated:</td> </tr> <tr class="highlight_gray_text"> <td class="indent1"> <ul> <li>Treat immediately, regardless of ALT or HBV DNA levels. ETV preferred.<sup>§</sup><sup>¥</sup> TDF may be used with close monitoring of renal function. Refer for liver transplant. </li> </ul> </td> </tr> <tr> <td class="centered" rowspan="2">+/–</td> <td rowspan="2">Undetectable</td> <td rowspan="2">Any ALT</td> <td>Compensated: Observe, recheck HBV DNA during follow-up, evaluate for other causes of cirrhosis if HBV DNA remains undetectable.</td> </tr> <tr> <td>Decompensated: Refer for liver transplant, recheck HBV DNA during follow-up, evaluate for other causes of cirrhosis.</td> </tr> </tbody></table></div><div class="graphic_footnotes">ALT: alanine aminotransferase; anti-HBe: antibody to hepatitis B e antigen; ETV: entecavir; HBeAg: Hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; PegIFN alfa: pegylated interferon alfa; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate; ULN: upper limit of normal.<br/>* Based upon findings on noninvasive testing or liver biopsy performed during the initial evaluation. Patients with advanced fibrosis determined by noninvasive methods should be evaluated using a second method, and if results are concordant, consider managing the same way as patients with cirrhosis.<br/>¶ The American Association for the Study of Liver Diseases (AASLD) recommends using an ALT &gt;35 U/L for men and &gt;25 U/L for women as the upper limit of normal (ULN) rather than local laboratory values.<br/>Δ Refer to UpToDate topic on "Hepatitis B virus: Overview of management" for a discussion of monitoring.<br/><font class="lozenge">◊</font> Refer to UpToDate topic on "Hepatitis B virus: Overview of management" for a discussion of indications for biopsy.<br/>§ Adefovir, lamivudine, and telbivudine are not recommended due to a high rate of resistance after the first year and/or weak antiviral activity.<br/>¥ Refer to UpToDate topic on "Hepatitis B virus: Overview of management" for a discussion of which agent to use.<br/>‡ Up to 50% of patients who achieve HBeAg seroconversion can experience a virologic relapse after discontinuing treatment with oral agents. Thus, some providers prefer to treat until HBsAg-loss.<br/>† For most patients, antiviral therapy should be continued indefinitely. However, treatment discontinuation may be considered in persons without cirrhosis who have demonstrated loss of HBsAg and in selected patients who have had undetectable serum HBV DNA for &gt;3 years and agree to close monitoring after stopping treatment. Persons who stop antiviral therapy should be monitored every month for the first six months. Refer to the UpToDate topic on management of hepatitis B virus infection for a detailed discussion of the risks and benefits of stopping antiviral therapy in this setting.<br/>** This includes HBeAg-positive adults with cirrhosis who seroconvert to anti-HBe on therapy.</div><div class="graphic_reference">References: <br/><ol>
<li>Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.</li></ol></div><div id="graphicVersion">Graphic 58520 Version 22.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
